By Alexander Bueso
Date: Tuesday 26 Jan 2021
LONDON (ShareCast) - (Sharecast News) - Regeneron Pharmaceuticals antibody cocktail severely curtails Covid-19 symptoms and infections, the results of a late-stage trial showed.
The trial involving 400 patients with at least one household member sick from Covid-19 showed that the two-antibody cocktail, known as REGEN-COV, completely cut symptomatic infections of the novel coronavirus.
Overall rates of infections meanwhile were reduced by approximately half.
A rival treatment from Eli Lilly, bamlanivimab, had shown a similar efficacy the week before, reducing Covid-19 infections among nursing home resident in a trial by 80%.
As of 1650 GMT, Regeneron shares had slipped 1.11% to $542.14.
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 578.05 |
Change Today | $ 8.88 |
% Change | 1.56 % |
52 Week High | $998.23 |
52 Week Low | $490.81 |
Volume | 745,708 |
Shares Issued | 107.80m |
Market Cap | $62,314m |
RiskGrade | 129 |
Strong Buy | 9 |
Buy | 11 |
Neutral | 4 |
Sell | 2 |
Strong Sell | 0 |
Total | 26 |
Time | Volume / Share Price |
16:00 | 107,698 @ $578.05 |
15:59 | 100 @ $578.25 |
15:59 | 146 @ $578.29 |
15:59 | 200 @ $578.09 |
15:59 | 100 @ $577.93 |
You are here: research